PortalPublikationenTenofovir disoproxil fumarate versus adefovir dipivoxil for ...

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Standard

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. / Marcellin, Patrick; Heathcote, E Jenny; Buti, Maria; Gane, Ed; Man, de; Robert, A; Krastev, Zahary; Germanidis, George; Lee, Sam S; Flisiak, Robert; Kaita, Kelly; Manns, Michael; Kotzev, Iskren; Buggisch, Peter; Buggisch, Peter; Weilert, Frank; Kurdas, Oya Ovung; Shiffman, Mitchell L; Trinh, Huy; Washington, Mary Kay; Sorbel, Jeff; Anderson, Jane; Snow-Lampart, Andrea; Mondou, Elsa; Quinn, Joe; Rousseau, Franck.

in: NEW ENGL J MED, Jahrgang 359, Nr. 23, 23, 2008, S. 2442-2455.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Marcellin, P, Heathcote, EJ, Buti, M, Gane, E, Man, D, Robert, A, Krastev, Z, Germanidis, G, Lee, SS, Flisiak, R, Kaita, K, Manns, M, Kotzev, I, Buggisch, P, Buggisch, P, Weilert, F, Kurdas, OO, Shiffman, ML, Trinh, H, Washington, MK, Sorbel, J, Anderson, J, Snow-Lampart, A, Mondou, E, Quinn, J & Rousseau, F 2008, 'Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.', NEW ENGL J MED, Jg. 359, Nr. 23, 23, S. 2442-2455. <http://www.ncbi.nlm.nih.gov/pubmed/19052126?dopt=Citation>

APA

Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., Man, D., Robert, A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Buggisch, P., Buggisch, P., Weilert, F., Kurdas, O. O., Shiffman, M. L., Trinh, H., ... Rousseau, F. (2008). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. NEW ENGL J MED, 359(23), 2442-2455. [23]. http://www.ncbi.nlm.nih.gov/pubmed/19052126?dopt=Citation

Vancouver

Marcellin P, Heathcote EJ, Buti M, Gane E, Man D, Robert A et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. NEW ENGL J MED. 2008;359(23):2442-2455. 23.

Bibtex

@article{1cc0ef5824334871bf3da672fda3c9ba,
title = "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.",
abstract = "BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of",
author = "Patrick Marcellin and Heathcote, {E Jenny} and Maria Buti and Ed Gane and de Man and A Robert and Zahary Krastev and George Germanidis and Lee, {Sam S} and Robert Flisiak and Kelly Kaita and Michael Manns and Iskren Kotzev and Peter Buggisch and Peter Buggisch and Frank Weilert and Kurdas, {Oya Ovung} and Shiffman, {Mitchell L} and Huy Trinh and Washington, {Mary Kay} and Jeff Sorbel and Jane Anderson and Andrea Snow-Lampart and Elsa Mondou and Joe Quinn and Franck Rousseau",
year = "2008",
language = "Deutsch",
volume = "359",
pages = "2442--2455",
journal = "NEW ENGL J MED",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

RIS

TY - JOUR

T1 - Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

AU - Marcellin, Patrick

AU - Heathcote, E Jenny

AU - Buti, Maria

AU - Gane, Ed

AU - Man, de

AU - Robert, A

AU - Krastev, Zahary

AU - Germanidis, George

AU - Lee, Sam S

AU - Flisiak, Robert

AU - Kaita, Kelly

AU - Manns, Michael

AU - Kotzev, Iskren

AU - Buggisch, Peter

AU - Buggisch, Peter

AU - Weilert, Frank

AU - Kurdas, Oya Ovung

AU - Shiffman, Mitchell L

AU - Trinh, Huy

AU - Washington, Mary Kay

AU - Sorbel, Jeff

AU - Anderson, Jane

AU - Snow-Lampart, Andrea

AU - Mondou, Elsa

AU - Quinn, Joe

AU - Rousseau, Franck

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of

AB - BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of

M3 - SCORING: Zeitschriftenaufsatz

VL - 359

SP - 2442

EP - 2455

JO - NEW ENGL J MED

JF - NEW ENGL J MED

SN - 0028-4793

IS - 23

M1 - 23

ER -